Ariosa Diagnostics s'apprête à présenter des données cliniques sur le test prénatal HarmonyTM lors de la rencontre annuelle de la société américaine de génétique humaine (American Society of Human Genetics)Télécharger le fichier PDF
San Jose, Calif., Nov. 5, 2012 – Ariosa Diagnostics today announced that it will present data from two
recent studies on non-invasive prenatal testing (NIPT) at the American Society of Human Genetics
(ASHG) Annual Meeting at The Moscone Center in San Francisco, Calif. from Nov. 6 - 11, 2012. The
studies highlight a directed cell-free (cfDNA) analysis method of NIPT.
A poster titled “Non-invasive Chromosomal Evaluation (NICE) Study: Results of a Multicenter,
Prospective, Cohort Study for Detection of Fetal Trisomy 21 and Trisomy 18,” examines the performance
of Ariosa’s Harmony Prenatal Test, a directed cfDNA analysis method of detecting fetal trisomies. The
NICE study represents the largest cohort study in NIPT. Pregnant women at gestational age 10 weeks or
later were enrolled from 50 clinical sites in the U.S. and Europe. The poster will be presented on
Thursday, Nov. 8, from 3:15 - 4:15 p.m. PST in The Moscone Center Exhibit Hall, Lower Level South.
A second poster titled “The Fetal Fraction of cell-free DNA in Maternal Plasma is Not Affected by a priori
Risk of Fetal Trisomy,” examines possible clinical factors that might influence the fetal fraction of cfDNA
in maternal plasma. The amount of fetal cfDNA in maternal plasma is a major determinant of the ability
to detect trisomy. A comparative analysis shows no difference in fetal cfDNA levels between high- and
low-risk pregnant women providing support that NIPT performance will be just as robust in a general
pregnancy population. This poster will be presented on Thursday, Nov. 8, from 3:15 - 4:15 p.m. PST in
The Moscone Center Exhibit Hall, Lower Level South.
For more information about Ariosa and the company’s directed cfDNA analysis method of NIPT, please
visit us at Booth #1609.